PT2476667E
(pt)
*
|
2003-02-26 |
2014-09-18 |
Sugen Inc |
Compostos de aminoheteroarilo como inibidores da proteína quinase
|
MXPA06009547A
(es)
*
|
2004-02-23 |
2007-01-26 |
Dana Farber Cancer Inst Inc |
Metodo para tratar el crecimiento celular anormal usando inhibidores de c-met y m-tor.
|
EP1719763A4
(en)
|
2004-02-27 |
2008-01-09 |
Eisai R&D Man Co Ltd |
NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2)
|
US7470701B2
(en)
*
|
2004-03-30 |
2008-12-30 |
Novartis Vaccines And Diagnostics, Inc. |
Substituted 2,5-heterocyclic derivatives
|
US8008301B2
(en)
|
2004-04-01 |
2011-08-30 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
PL1735278T3
(pl)
*
|
2004-04-01 |
2010-06-30 |
Lilly Co Eli |
Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
|
JP4942654B2
(ja)
|
2004-08-23 |
2012-05-30 |
イーライ リリー アンド カンパニー |
ヒスタミンh3受容体薬剤、製剤及び治療的使用
|
WO2006021881A2
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
|
MX2007001986A
(es)
*
|
2004-08-26 |
2007-05-10 |
Pfizer |
Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
|
CA2578066C
(en)
|
2004-08-26 |
2011-10-11 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
BRPI0514422A
(pt)
*
|
2004-08-26 |
2008-06-10 |
Pfizer |
biotransformação enantioseletiva para o preparo de intermediários do inibidor de proteìna tirosina quinase
|
GT200600042A
(es)
*
|
2005-02-10 |
2006-09-27 |
Aventis Pharma Inc |
Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
|
EP1853610A1
(en)
*
|
2005-03-03 |
2007-11-14 |
Sirtris Pharmaceuticals, Inc. |
N-phenyl benzamide derivatives as sirtuin modulators
|
US20060258672A1
(en)
*
|
2005-05-13 |
2006-11-16 |
Joseph Barbosa |
Multicyclic compounds and methods of their use
|
WO2007019344A1
(en)
*
|
2005-08-04 |
2007-02-15 |
Sirtris Pharmaceuticals, Inc. |
Imidazo [2,1-b] thiayole derivatives as sirtuin modulating compounds
|
US7855289B2
(en)
*
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
US8093401B2
(en)
*
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
US8088928B2
(en)
*
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
EP1889836B1
(en)
|
2005-08-24 |
2013-06-12 |
Eisai R&D Management Co., Ltd. |
Novel pyridine derivative and pyrimidine derivative (3)
|
KR101146852B1
(ko)
*
|
2005-12-05 |
2012-05-16 |
화이자 프로덕츠 인크. |
C?met/hgfr 억제제의 다형체
|
DK1959955T3
(da)
*
|
2005-12-05 |
2011-02-07 |
Pfizer Prod Inc |
Fremgangsmåde til behandling af abnorm cellevækst
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
US7723330B2
(en)
|
2006-03-07 |
2010-05-25 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
EP2004625B1
(en)
*
|
2006-03-22 |
2009-12-30 |
Vertex Pharmaceuticals Incorporated |
C-met protein kinase inhibitors for the treatment of proliferative disorders
|
SI2450437T1
(sl)
|
2006-04-14 |
2017-12-29 |
Cell Signaling Technology Inc. |
Okvarjenost genov in mutantna ALK kinaza v človeških solidnih tumorjih
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
US7601716B2
(en)
|
2006-05-01 |
2009-10-13 |
Cephalon, Inc. |
Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
|
WO2007139930A2
(en)
*
|
2006-05-26 |
2007-12-06 |
Bayer Healthcare Llc |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
CA2655128A1
(en)
*
|
2006-06-08 |
2007-12-21 |
Array Biopharma Inc. |
Quinoline compounds and methods of use
|
US7683060B2
(en)
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
AU2007288793B2
(en)
*
|
2006-08-23 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
US7790885B2
(en)
*
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
WO2008042867A2
(en)
*
|
2006-09-29 |
2008-04-10 |
Emiliem Inc. |
Modulators of multiple kinases
|
CA2669111C
(en)
|
2006-10-23 |
2016-04-12 |
Cephalon, Inc. |
Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
|
GB0621607D0
(en)
*
|
2006-10-31 |
2006-12-06 |
Chroma Therapeutics Ltd |
Inhibitors of c-Met
|
PL2099447T3
(pl)
|
2006-11-22 |
2013-06-28 |
Incyte Holdings Corp |
Imidazotriazyny i imidazopirmidyny jako inhibitory kinaz
|
CL2007003609A1
(es)
|
2006-12-14 |
2008-07-25 |
Bayer Schering Pharma Ag |
Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
|
WO2008087736A1
(ja)
*
|
2007-01-19 |
2008-07-24 |
Ube Industries, Ltd. |
アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
|
WO2008088881A1
(en)
|
2007-01-19 |
2008-07-24 |
Xcovery, Inc. |
Kinase inhibitor compounds
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
PT2134685E
(pt)
*
|
2007-04-16 |
2015-11-25 |
Abbvie Inc |
Derivados de índole não substituídos na posição 7 como inibidores de mcl-1
|
US8263585B2
(en)
|
2007-05-04 |
2012-09-11 |
Novartis Ag |
Organic compounds
|
CL2008001822A1
(es)
*
|
2007-06-20 |
2009-03-13 |
Sirtris Pharmaceuticals Inc |
Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
|
WO2009012283A1
(en)
|
2007-07-17 |
2009-01-22 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EP2173722B1
(en)
*
|
2007-07-26 |
2012-08-29 |
Novartis AG |
Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
|
JP5973131B2
(ja)
|
2007-09-13 |
2016-08-23 |
コデクシス, インコーポレイテッド |
アセトフェノンの還元のためのケトレダクターゼポリペプチド
|
AU2008317107B2
(en)
*
|
2007-10-23 |
2013-09-12 |
Allergan, Inc. |
Therapeutic substituted lactams
|
KR20100092000A
(ko)
*
|
2007-11-01 |
2010-08-19 |
서트리스 파마슈티컬즈, 인코포레이티드 |
시르투인 조절제로서의 아미드 유도체
|
CA2705138A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Sirtris Pharmaceuticals, Inc. |
Solubilized thiazolopyridines
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
WO2009073224A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Ambit Biosciences Corp. |
Methods of treating certain diseases using pyrimidine derivatives
|
US20090227556A1
(en)
*
|
2008-01-31 |
2009-09-10 |
Eisai R&D Management Co., Ltd. |
Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
|
JPWO2009096198A1
(ja)
*
|
2008-02-01 |
2011-05-26 |
一般社団法人ファルマIp |
新規ビアリール誘導体
|
EP2265270A1
(en)
*
|
2008-02-04 |
2010-12-29 |
OSI Pharmaceuticals, Inc. |
2-aminopyridine kinase inhibitors
|
AR070317A1
(es)
*
|
2008-02-06 |
2010-03-31 |
Osi Pharm Inc |
Furo (3,2-c) piridina y tieno (3,2-c) piridinas
|
EP2248810A4
(en)
*
|
2008-02-18 |
2011-05-25 |
Eisai R&D Man Co Ltd |
METHOD FOR PRODUCING A PHENOXYPYRIDINE DERIVATIVE
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
FR2928923B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
|
FR2928922B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
|
FR2928924B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
|
US20110039860A1
(en)
*
|
2008-05-07 |
2011-02-17 |
Cangming Yang |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
HUE034716T2
(hu)
|
2008-05-21 |
2018-02-28 |
Incyte Holdings Corp |
2-Fluor-N-metil-4-[7-(kinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamid sói és eljárások ezek elõállítására
|
US8697866B2
(en)
*
|
2008-06-19 |
2014-04-15 |
Xcovery Holding Company Llc |
Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
|
WO2010025414A2
(en)
*
|
2008-08-29 |
2010-03-04 |
Genentech, Inc. |
Diagnostics and treatments for vegf-independent tumors
|
WO2010046780A2
(en)
*
|
2008-10-22 |
2010-04-29 |
Institut Pasteur Korea |
Anti viral compounds
|
WO2010059771A1
(en)
|
2008-11-20 |
2010-05-27 |
Osi Pharmaceuticals, Inc. |
Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
|
EP2375904B1
(en)
*
|
2008-12-09 |
2014-05-28 |
Merck Sharp & Dohme Corp. |
Biaryl carboxamides
|
KR101745331B1
(ko)
|
2008-12-19 |
2017-06-09 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 키나제의 억제제로서 유용한 피라진 유도체
|
WO2010071853A1
(en)
|
2008-12-19 |
2010-06-24 |
Sirtris Pharmaceuticals, Inc. |
Thiazolopyridine sirtuin modulating compounds
|
JP2012102018A
(ja)
*
|
2009-03-03 |
2012-05-31 |
Astellas Pharma Inc |
アミド化合物
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
DE102009056886A1
(de)
|
2009-12-03 |
2011-06-09 |
Bayer Schering Pharma Aktiengesellschaft |
cMet-Inhibitoren zur Behandlung der Endometriose
|
CN102812027B
(zh)
|
2010-02-03 |
2015-01-07 |
因西特公司 |
作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪
|
EP2566858A2
(en)
*
|
2010-05-04 |
2013-03-13 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
WO2011143423A2
(en)
*
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
AU2011253025A1
(en)
|
2010-05-12 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
EP2569287B1
(en)
|
2010-05-12 |
2014-07-09 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
JP2013526570A
(ja)
|
2010-05-14 |
2013-06-24 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
縮合二環式キナーゼ阻害剤
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
US10010439B2
(en)
|
2010-06-13 |
2018-07-03 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
US10420665B2
(en)
|
2010-06-13 |
2019-09-24 |
W. L. Gore & Associates, Inc. |
Intragastric device for treating obesity
|
US9526648B2
(en)
|
2010-06-13 |
2016-12-27 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
US8628554B2
(en)
|
2010-06-13 |
2014-01-14 |
Virender K. Sharma |
Intragastric device for treating obesity
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
EP2593434A1
(en)
|
2010-07-16 |
2013-05-22 |
Purdue Pharma LP |
Pyridine compounds as sodium channel blockers
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
CA2813607C
(en)
|
2010-10-08 |
2021-08-31 |
Xcovery Holding Company, Llc |
Substituted pyridazine carboxamide compounds
|
PT2646448T
(pt)
|
2010-11-29 |
2017-10-04 |
Osi Pharmaceuticals Llc |
Inibidores macrocíclicos de cinases
|
GB201021103D0
(en)
|
2010-12-13 |
2011-01-26 |
Univ Leuven Kath |
New compounds for the treatment of neurodegenerative diseases
|
CA2826892A1
(en)
*
|
2011-02-24 |
2012-08-30 |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Phosphorus containing compounds as protein kinase inhibitors
|
US9145390B2
(en)
|
2011-03-03 |
2015-09-29 |
Concert Pharmaceuticals, Inc. |
Derivatives of pyrazole-substituted amino-heteroaryl compounds
|
JO3438B1
(ar)
|
2011-04-13 |
2019-10-20 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
US20140113824A1
(en)
|
2011-05-10 |
2014-04-24 |
Bayer Intellectual Property Gmbh |
Bicyclic (thio)carbonylamidines
|
JP2014513724A
(ja)
|
2011-05-16 |
2014-06-05 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
融合二環キナーゼ阻害剤
|
EP2723746A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
WO2013013308A1
(en)
*
|
2011-07-27 |
2013-01-31 |
Beta Pharma Canada Inc. |
Spirocyclic molecules as protein kinase inhibitors
|
RU2014102935A
(ru)
|
2011-08-02 |
2015-09-10 |
Пфайзер Инк. |
Кризотиниб для применения в лечении рака
|
BR112014007690B1
(pt)
|
2011-09-30 |
2022-10-04 |
Vertex Pharmaceuticals Incorporated |
Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas
|
KR102184246B1
(ko)
|
2011-09-30 |
2020-12-01 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 키나제의 억제제로서 유용한 화합물의 제조 방법
|
CN104169286B
(zh)
|
2012-03-06 |
2016-06-08 |
辉瑞大药厂 |
用于治疗增殖性疾病的大环衍生物
|
US9206127B2
(en)
|
2012-03-16 |
2015-12-08 |
Purdue Pharm, L.P. |
Substituted pyridines as sodium channel blockers
|
RS56673B1
(sr)
|
2012-04-05 |
2018-03-30 |
Vertex Pharma |
Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US10301290B2
(en)
|
2012-04-13 |
2019-05-28 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
CN103387535B
(zh)
*
|
2012-05-10 |
2016-06-01 |
广东东阳光药业有限公司 |
取代的炔基吡啶化合物及其使用方法和用途
|
WO2013177092A1
(en)
*
|
2012-05-23 |
2013-11-28 |
Sunshine Lake Pharma Co., Ltd. |
Substituted alkynyl pyridine compounds and methods of use
|
SG10201805807PA
(en)
|
2012-06-26 |
2018-08-30 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
GB201211310D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Chroma Therapeutics Ltd |
CSF-1R kinase inhibitors
|
AU2013318618B2
(en)
|
2012-09-24 |
2017-04-06 |
Ventana Medical Systems, Inc. |
Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker
|
US8999632B2
(en)
|
2012-10-04 |
2015-04-07 |
Vertex Pharmaceuticals Incorporated |
Method for measuring ATR inhibition mediated increases in DNA damage
|
WO2014081816A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Concert Pharmaceuticals, Inc. |
Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
|
CN107501275B
(zh)
|
2012-12-07 |
2019-11-22 |
沃泰克斯药物股份有限公司 |
可用作atr激酶抑制剂的化合物
|
US9714252B2
(en)
|
2012-12-20 |
2017-07-25 |
Purdue Pharma L.P. |
Cyclic sulfonamides as sodium channel blockers
|
EP2937337A4
(en)
|
2012-12-21 |
2016-06-22 |
Eisai R&D Man Co Ltd |
AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
|
US9708295B2
(en)
*
|
2013-02-02 |
2017-07-18 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Substituted 2-aminopyridine protein kinase inhibitor
|
EP2970286A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
KR20160061911A
(ko)
|
2013-04-08 |
2016-06-01 |
데니스 엠. 브라운 |
최적하 투여된 화학 화합물의 치료 효과
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
WO2015034729A1
(en)
*
|
2013-09-05 |
2015-03-12 |
Calitor Sciences, Llc |
Substituted pyridine compounds and methods of use
|
US20160214961A1
(en)
*
|
2013-09-10 |
2016-07-28 |
Shilpa Medicare Limited |
Novel salts of crizotinib and their preparation
|
RU2550346C2
(ru)
|
2013-09-26 |
2015-05-10 |
Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" |
Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
|
DK3053923T3
(en)
|
2013-09-30 |
2018-07-23 |
Korea Res Inst Chemical Tech |
TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
RU2720408C2
(ru)
|
2013-12-06 |
2020-04-29 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения ингибиторов atr киназы (варианты)
|
EP3083583B1
(en)
|
2013-12-20 |
2020-11-18 |
Sagimet Biosciences Inc. |
Heterocyclic modulators of lipid synthesis and combinations thereof
|
CN103755627B
(zh)
*
|
2014-01-09 |
2016-02-17 |
定陶县友帮化工有限公司 |
2-氨基-3-羟基-5-氯吡啶的合成方法
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
CN107002119A
(zh)
|
2014-03-24 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
|
US10730866B2
(en)
|
2014-04-07 |
2020-08-04 |
Purdue Pharma L.P. |
Indole derivatives and use thereof
|
US10052332B2
(en)
|
2014-04-29 |
2018-08-21 |
Emory University |
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
|
WO2015172747A1
(en)
*
|
2014-05-16 |
2015-11-19 |
Zhaoyin Wang |
Spirocyclic molecules as mth1 inhibitors
|
AU2015271030B2
(en)
|
2014-06-05 |
2019-05-16 |
Vertex Pharmaceuticals Incorporated |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
|
ES2733847T3
(es)
|
2014-06-17 |
2019-12-03 |
Vertex Pharma |
Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR
|
WO2016019909A1
(zh)
*
|
2014-08-07 |
2016-02-11 |
江苏豪森药业股份有限公司 |
一种抗癌化合物的新晶型及其制备方法和用途
|
US10112939B2
(en)
|
2014-08-21 |
2018-10-30 |
Bristol-Myers Squibb Company |
Tied-back benzamide derivatives as potent rock inhibitors
|
TWI721954B
(zh)
|
2014-08-28 |
2021-03-21 |
日商衛材R&D企管股份有限公司 |
高純度喹啉衍生物及其生產方法
|
WO2016061097A1
(en)
|
2014-10-13 |
2016-04-21 |
Atrin Pharmaceuticals LLC |
Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
|
GB2535427A
(en)
|
2014-11-07 |
2016-08-24 |
Nicoventures Holdings Ltd |
Solution
|
AR102537A1
(es)
*
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
JP6902466B2
(ja)
*
|
2014-11-07 |
2021-07-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
ミオカルディン関連転写因子および血清応答因子(mrtf/srf)媒介性遺伝子転写の阻害剤ならびにその使用方法
|
CN107207471B
(zh)
|
2014-12-02 |
2020-06-26 |
伊尼塔公司 |
用于治疗神经母细胞瘤的组合
|
EP3789027A1
(en)
|
2015-01-13 |
2021-03-10 |
Kyoto University |
Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
|
RU2017128583A
(ru)
|
2015-02-25 |
2019-03-25 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Способ ослабления горечи хинолинового производного
|
MA41598A
(fr)
*
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
US10464896B2
(en)
|
2015-06-11 |
2019-11-05 |
Basilea Pharmaceutica International AG |
Efflux-pump inhibitors and therapeutic uses thereof
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
US10405627B2
(en)
*
|
2015-07-14 |
2019-09-10 |
Michael Charles Boland, III |
Luggage with fold out table
|
WO2017059357A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
AU2016370846B2
(en)
|
2015-12-18 |
2022-08-25 |
Ignyta, Inc. |
Combinations for the treatment of cancer
|
WO2017161004A1
(en)
|
2016-03-15 |
2017-09-21 |
University Of South Florida |
PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
|
WO2017180723A1
(en)
|
2016-04-12 |
2017-10-19 |
Atrin Pharmaceuticals LLC |
Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
|
US10779980B2
(en)
|
2016-04-27 |
2020-09-22 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
EP3463355A4
(en)
*
|
2016-05-26 |
2020-07-29 |
Sonic Master Limited |
DUX4 MODULATORS FOR REGULATING MUSCLE FUNCTION
|
TWI646094B
(zh)
|
2016-06-01 |
2019-01-01 |
大陸商貝達藥業股份有限公司 |
Crystal form of inhibitory protein kinase active compound and application thereof
|
WO2018110669A1
(en)
|
2016-12-15 |
2018-06-21 |
Ono Pharmaceutical Co., Ltd. |
Activator of trek (twik related k+ channels) channels
|
CN106866627B
(zh)
*
|
2017-01-24 |
2021-09-14 |
南方医科大学 |
3-(1-(氨基吡啶氧基)乙基)苯甲酰胺衍生物及其合成方法和应用
|
US11028058B2
(en)
|
2017-07-18 |
2021-06-08 |
Nuvation Bio Inc. |
Heterocyclic compounds as adenosine antagonists
|
JP2020527593A
(ja)
|
2017-07-18 |
2020-09-10 |
ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. |
1,8−ナフチリジノン化合物およびその使用
|
JP7203083B2
(ja)
|
2017-07-19 |
2023-01-12 |
イグナイタ インコーポレイテッド |
エントレクチニブを含む薬学的組成物
|
EP3697390A1
(en)
|
2017-10-17 |
2020-08-26 |
Ignyta, Inc. |
Pharmaceutical compositions and dosage forms
|
CN107794282B
(zh)
*
|
2017-11-20 |
2020-12-25 |
浙江工业大学 |
一种克唑替尼手性中间体的制备方法及菌株
|
WO2019154665A1
(en)
*
|
2018-02-07 |
2019-08-15 |
Basf Se |
New pyridine carboxamides
|
HUE058998T2
(hu)
*
|
2018-03-15 |
2022-09-28 |
Fujian Haixi Pharmaceuticals Co Ltd |
Heteroaril vegyületek, mint kináz inhibitorok
|
CN110372664A
(zh)
*
|
2018-04-13 |
2019-10-25 |
华东理工大学 |
选择性jak2抑制剂及其应用
|
CN110396087A
(zh)
*
|
2018-04-25 |
2019-11-01 |
珠海宇繁生物科技有限责任公司 |
Hpk1激酶抑制剂、制备方法及其应用
|
WO2019206049A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Zhuhai Yufan Biotechnologies Co., Ltd |
Hpk1 inhibitors, preparation method and application thereof
|
CN108947895B
(zh)
*
|
2018-08-22 |
2021-09-24 |
肇庆中彩机电技术研发有限公司 |
一种抗癌活性的化合物
|
WO2020150677A1
(en)
*
|
2019-01-18 |
2020-07-23 |
Nuvation Bio Inc. |
Heterocyclic compounds as adenosine antagonists
|
WO2020150674A1
(en)
*
|
2019-01-18 |
2020-07-23 |
Nuvation Bio Inc. |
Heterocyclic compounds as adenosine antagonists
|
JP2022523473A
(ja)
|
2019-01-18 |
2022-04-25 |
ニューベイション・バイオ・インコーポレイテッド |
1,8-ナフチリジジノン化合物およびそれらの使用
|
JP7345901B2
(ja)
|
2019-05-14 |
2023-09-19 |
テリジーン リミテッド |
キナーゼ阻害剤として有用な置換大員環類
|
KR102426921B1
(ko)
|
2019-09-24 |
2022-07-29 |
주식회사 이노보테라퓨틱스 |
헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
KR102344185B1
(ko)
*
|
2020-02-26 |
2021-12-27 |
계명대학교 산학협력단 |
신규한 Pim 키나아제 억제제 및 이의 용도
|
WO2021196655A1
(zh)
*
|
2020-04-03 |
2021-10-07 |
中国药科大学 |
含苯并咪唑结构的化合物及其制备方法与用途
|
CN113493437B
(zh)
*
|
2020-04-03 |
2022-07-26 |
中国药科大学 |
含苯并咪唑结构的化合物及其制备方法和用途
|
WO2023086671A1
(en)
*
|
2021-11-15 |
2023-05-19 |
The Broad Institute, Inc. |
Compounds, compositions, and methods for inducing antimicrobial intracellular activity and for preventing and treating microbial infections
|